Should you buy these pharma stocks with over 80% return in a year?

Highlights  For the half-year ended 30 June 2021, Oxford Biomedica’s revenue increased by 139% year-on-year to £81.3 million compa...

MyHealthChecked (M3HC) & Alliance (APH): Are these pharma stocks a b...

Highlights  MyHealthChecked had recently acquired Nell Health Ltd, a technology-led genetic-testing platform and provider of personalised nutr...

AstraZeneca (LON: AZN) to acquire Caelum Biosciences: Buy alert?

Highlights Anglo-Swedish pharma company, AstraZeneca’s Alexion is set to acquire the remaining stake in rare disease biotech firm Caelum Bios...

Sareum (SAR) returns 700% in a year: Is this small-cap share still a...

HIGHLIGHTS Saerum raised £2.37 million in June 2021 through two subscription contracts with high-net-worth individuals. In July 2021, the co...

Synairgen & Omega Diagnostics: 2 AIM pharma stocks for a healthy por...

Highlights  Omega Diagnostics filed for CE-mark on Covid-19 antigen self-test ‘Visitect’. Synairgen, last year generated £8...

Open Orphan (ORPH) & Angle (AGL): 2 AIM pharma stocks to buy in Sept...

Pharma stocks listed on AIM present attractive investment opportunities for investors seeking to diversify their portfolios, and they simultaneously o...

UK may offer Covid-19 jabs to 12- 15-year-olds. Stocks to look at

Highlights  NHS England to prepare for a potential extension of the Covid vaccination programme to all 12 to 15-year-olds from early September...

Faron (LON: FARN) & Novacyt (LON: NCYT) shares. Should you buy them...

Highlights  Faron Pharmaceuticals Oy share prices suffered a sharp correction of around 7 per cent. For the H1 2021 ended 30 June 2021, Novac...

Inspira supports Vectura’s (LON: VEC) £1.1bn acquisition by Philip M...

Highlights  Inspira Pharmaceuticals comes out to support Vecutra’s £1.1 billion takeover by US-based Philip Morris International a...

UK’s Psychedelic sector and potential investment opportunities

Highlights Decades of research has shown Psychedelic substance such as LSD and Psilocybin can treat the mental disorder more efficiently than conve...

Is it the right time to invest in these 5 FTSE listed cannabis stock...

Very recently, in 2018 the UK legalised the medicinal use of cannabis. Medical cannabis, which is used to treat the pain and specific illnesses was fi...

Pfizer booster shot - Which other vaccines may require booster doses...

Summary  According to BioNTech, a booster shot of the two-shot Pfizer vaccine is expected to serve as a better strategy to fight new variant t...

Pfizer and Flynn in the dock for overcharging NHS for anti-epilepsy...

Summary  The Competition and Markets Authority has accused pharma major Pfizer and Flynn of overcharging for the anti-epileptic drug. Both Pf...

Why have Pfizer and Moderna raised prices for vaccines in the EU?

Summary US-based COVID-19 vaccine manufacturers Pfizer and Moderna increased prices of their vaccines in the latest European Union supply contracts...

5 top FTSE healthcare stocks below £1

Summary  Investors often chose to invest in low-priced stocks in the healthcare sector, as few of such firms will emerge as big gainers in the...

AstraZeneca’s (LON: AZN) shares and the latest buzz around

AstraZeneca (LON: AZN), the pharmaceutical major,  which has been news for last some time due to its Covid-19 vaccine, is once again creating buz...

Lens on 5 AIM listed pharma stocks as CMA slaps £260-million fine on...

Summary  CMA slapped fines of over £260 million on drug makers after investigations revealed NHS was overcharged close to a decade for h...

Which are the 10 biggest FTSE-listed healthcare stocks?

Summary The pandemic has made people more aware of the importance of research and development in pharmaceuticals, making Healthcare stocks the flav...

Tristel receives three product approvals in the US, Canada, and Sout...

Summary Tristel received three regulatory approvals for its different categories of product. In the US, the company got approval for surface disin...

More sales, more profits, but less dividends: Emma Walmsley’s roadma...

GlaxoSmithKline’s (LON:GSK) CEO Emma Walmsley has said that by 2031, the company plans to make sales of over £33 billion and increase adju...